Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfizer Announces Partnership with Shanghai Institutes for Biological Sciences for Drug Discovery Activities

Published: Thursday, July 30, 2009
Last Updated: Thursday, July 30, 2009
Bookmark and Share
Pfizer will provide US$500,000 each year over three years to fund health-related fundamental research projects at SIBS.

Pfizer has announced a joint initiative with the Shanghai Institutes for Biological Sciences (SIBS) to support fundamental research in China.

As part of the initiative, Pfizer China will provide US$500,000 each year over three years to fund health-related fundamental research projects at SIBS and its application to drug discovery and development programs in the country. This is the latest in a series of Pfizer initiatives aimed at supporting China as it becomes one of the leading contributors to healthcare innovation worldwide.

“This collaboration represents a major commitment by Pfizer to fundamental research and development in China,” said Jeff Kindler, Pfizer’s chief executive officer. “Our investment is an example of our dedication to leading healthcare innovation, not only in the last mile of drug development, but from much earlier stages of exploration into basic healthcare principles. Innovation in these areas has the potential to truly alter the way we look at healthcare over the next 20 years.”

Fundamental research, also known as basic research, is generally defined as pure scientific investigation to gain knowledge and understanding about the physical world. While this type of research does not necessarily lead to immediate commercial gain, it has the potential to lead to important new discoveries that ultimately improve healthcare and help save lives.

“Our choice of Shanghai Institutes for Biological Sciences as a research partner demonstrates our high regard for the scientific expertise and capabilities of SIBS,” said Martin Mackay, President, Pfizer Global Research and Development. “China is increasingly seen as a source for innovative healthcare research, and we are proud of our ongoing investment in the outstanding science and people here.” Research projects will be selected and developed jointly by Pfizer and SIBS scientists.

“Today marks a new milestone in the collaboration between SIBS and Pfizer,” said Jiarui Wu, Vice President of SIBS, “The agreement injects momentum into the innovation activities at SIBS and Pfizer, and this collaboration will definitely accelerate the development of new healthcare solutions.”

Pfizer’s China Research and Development Center, a state-of-the-art facility that provides global drug development support capabilities, research collaborations, and strategic alliance opportunities to China and the Asian region, is based in Shanghai. It employs more than 330 staff and is the largest R&D center for a multinational pharmaceutical company in China.

“Strategic alliances such as this one are needed to increase the opportunities to produce the science, technology and product candidates that lead to new medicines,” said Al Gabor, regional president for Pfizer’s North Asia, India, Pakistan, and Thailand region. “This collaboration with SIBS is a testament to Pfizer’s continued commitment to the city of Shanghai, and to China as a whole.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer and Private Access Announce Plans to Develop Online Community to Accelerate Clinical Research
Privacy-enhanced search technology addresses privacy concerns to increase patient participation.
Monday, August 31, 2009
Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Pharmacy on Demand
New, portable system can be configured to produce different drugs.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Countless New, Cleaner Uses of Methane
Chemists have demonstrated the potential to use methane as a versatile chemical building block with which to make more complex molecules.
New Way to Control Chemical Reactions
Scientists have harnessed static electricity to control chemical reactions for the first time, in a breakthrough that could bring cleaner industry and cheaper nanotechnology.
Tiny 'Flasks' Speed Up Chemical Reactions
Self-assembling nanosphere clusters may improve everything from drug synthesis to drug delivery.
The Manufacturing Challenges of Nanotechnology
Head of NanoManufacturing at the Department of Engineering’s Institute for Manufacturing (IfM) Dr Michaël de Volder explains why manufacturing carbon nanotubes is so difficult – and so important.
New Material Lays Waste to Mercury Pollution
A brand new, dirt cheap, non-toxic polymer that literally sucks mercury out of water and soil is set to become a game changer in the battle against one of the world’s most reviled pollutants.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!